전체메뉴

Journal of Pharmacopuncture

Article Search

JoP

Cross Mark

CrossMark Policy

Crossmark
Applying the CrossMark icon is a commitment by Korea Pharmacopuncture Institute to maintain the content published and alert readers to changes if and when they occur.

What is Crossmark?
CrossMark, a multi-publisher initiative from CrossRef, provides a standard way for readers to locate the authoritative version of a document. Elsevier recognizes the importance of the integrity and completeness of the scholarly record to researchers and librarians and attaches the highest importance to maintaining trust in the authority of its electronic archive. Clicking on the CrossMark icon will inform the reader of the current status of a document and may also provide additional publication record information about the document.

Permanency of content

All content published in Journal of Pharmacopuncture is permanently published, regardless of the outcome of the peer review that follows after publication. All versions of all articles that have passed peer review are permanently archived in PubMed Central.

Authors can revise, change and update their articles by publishing new versions, which are added to the article’s history; however, the individual versions, once published, cannot be altered or withdrawn and are permanently available on the Journal of Pharmacopuncture website. Journal of Pharmacopuncture participates in the CrossMark scheme, a multi-publisher initiative that has developed a standard way for readers to locate the current version of a piece of content. By applying the CrossMark policies, Journal of Pharmacopuncture is committed to maintaining the content it publishes and to alerting readers to changes if and when they occur.

Clicking on the CrossMark logo (at the top of each Journal of Pharmacopuncture article) will give you the current status of an article and direct you to the latest published version; it may also give you additional information such as new referee reports.

In order to maintain the integrity and completeness of the scholarly record, we will apply the following policies when published content needs to be corrected; these policies take into account current best practice in the scholarly publishing and library communities:

  • Correction
    In traditional journals, where articles are peer-reviewed before publication, Corrections (or Errata) are published to alert readers to errors in the article that became apparent following the publication of the final article. By contrast, articles in Journal of Pharmacopuncture undergo peer review post publication and publication is not ‘final’ as new versions can be added at any stage. Possible mistakes that come to light during the peer review process may be highlighted in the published referee reports, which are part of the article. Authors can publish revised versions, and any errors that become apparent during peer review or later can be corrected through the publication of new versions. Corrections and changes relative to the previous version are always summarized in the ‘Amendments’ section at the start of a new version.
  • Retraction
    This action is reserved for articles that are seriously flawed and so the findings or conclusions cannot be relied upon. Articles may be retracted for several reasons, including:
    • honest errors reported by the authors (for example, errors due to the mixing up of samples or use of a scientific tool or equipment that is found subsequently to be faulty)
    • research misconduct (data fabrication)
    • duplicate or overlapping publication
    • fraudulent use of data
    • plagiarism
    • unethical research
    For any retracted article, the reason for retraction and who is instigating the retraction will be clearly stated in the Retraction notice. The retraction notice will be linked to the retracted article (which usually remains on the site) and the article will be clearly marked as retracted (including the PDF).
    An article is usually only retracted at the authors’ request or by the publisher in response to an institutional investigation. It is important to note in the context of Journal of Pharmacopuncture’s publication model, that ‐ as in traditional journals ‐ a retracted article is not ‘unpublished’ or ‘withdrawn’ in order for it to be published elsewhere. The reasons for retraction are usually so serious that the whole study, or large parts of it, are not appropriate for inclusion in the scientific literature anywhere.
  • Removal
    The removal of an article would only be undertaken where legal limitations have been placed upon the publisher, copyright holder or author(s), for example, if the article is clearly defamatory or infringes others’ legal rights, or if the article is the subject of a court order. The bibliographic information for a removed article will be retained on the site along with information regarding the circumstances that led to its removal.
    Under rare circumstances, for example, if false or inaccurate data have been published that, if acted upon, pose a serious health risk, the original incorrect version(s) may be removed and a corrected version published. The reason for this partial removal would be clearly stated on the latest version.
  • Editorial Note
    If there is a potential, not yet resolved, problem with an article, it may be appropriate to alert readers with an Editorial Note. Such an Editorial Note may be added to the article, for example, if Journal of Pharmacopuncture receives information that research or publication misconduct might have taken place, or that there is a serious dispute between authors or between the authors and third parties. The Editorial Note will usually be posted while further investigations take place and until a more permanent solution has been found (e.g. the publication of a revised ‘corrected’ version, or a Retraction).
  • Expression of Concern
    In rare cases, Journal of Pharmacopuncture may decide to publish an Expression of Concern, which is linked to the problematic article, if there are serious concerns about an article but no conclusive evidence can be obtained that would unequivocally justify a Retraction. This may include:
    • if there is inconclusive evidence of research or publication misconduct
    • there is evidence that there are problems with the article, but the authors’ institution will not investigate the case
    • an investigation into alleged misconduct has not been impartial or conclusive

    DOI : 10.3831/KPI.CrossMark.Policy

Journal Info

JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY
March, 2021
Vol.24 No.1

pISSN 2093-6966
eISSN 2234-6856
Quarterly

Archives >

Editorial Office

Fax
Fax +82-2-2658-9136

Most Read / Downloaded

  • Review Article2020-06-30

    Abstract : Coronavirus disease-19 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). Currently, the management of patients with COVID-19 depends mainly on repurposed drugs which include chloroquine, hydroxychloroquine, lopinavir/ritonavir, ribavirin, remdesivir, favipiravir, umifenovir, interferon-α, interferon-β and others. In this review, the potential of Nigella sativa (black cumin seeds) to treat the patients with COVID-19 analyzed, as it has shown to possess antiviral, antioxidant, anti-inflammatory, anticoagulant, immunomodulatory, bronchodilatory, antihistaminic, antitussive, antipyretic and analgesic activities. PubMed, Google Scholar, Science Direct, Directory of open access journals (DOAJ) and reference lists were searched to identify articles associated with antiviral and other properties of N.sativa related to the signs and symptoms of COVID-19. Various randomized controlled trials, pilot studies, case reports and in vitro and in vivo studies confirmed that N.sativa has antiviral, antioxidant, anti-inflammatory, immunomodulatory, bronchodilatory, antihistaminic, antitussive activities related to causative oraganism and signs and symptoms of COVID-19. N. sativa could be used as an adjuvant therapy along with repurposed conventional drugs to manage the patients with COVID-19.

    Abstract
  • Systematic Review2020-06-30

    Bee Venom Acupuncture for Shoulder Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials

    Lei Shen1,†, Jong Ha Lee2,†, Jong Cheon Joo1, Soo Jung Park3,*, and Yung Sun Song4,*
    J Pharmacopuncture 2020; 23(2): 44-53 https://doi.org/10.3831/KPI.2020.23.008

    Abstract : ObjectivesOur review aimed to summarize and evaluate evidence on the effectiveness of bee venom acupuncture (BVA) in the treatment of shoulder pain.MethodsRandomized controlled trials (RCTs) evaluating the effectiveness of BVA on shoulder pain were searched up to October 2019 in 11 electronic databases (Medline, Embase, CENTRAL, CiNii, CNKI, VIP, Wanfang, Kmbase, NDSL, RISS, OASIS). The methodological quality of the included RCTs were evaluated using Cochrane Risk of Bias tool and a meta-analysis was performed.ResultsSeven studies were included in the review, and four studies were included in the meta-analysis. Comparing BVA plus conventional therapy (CT) with saline injection plus CT, it showed an effect in favor of BVA plus CT in visual analog scale (VAS) and pain rating scale (PRS) (p = 0.02, p = 0.009, respectively). Comparing BVA plus physiotherapy (PT) with saline injection plus PT, it showed that there was no significant difference in VAS and verbal rating scale (VRS) between the two groups.ConclusionThis systematic review and meta-analysis suggest that BVA could be beneficial as an adjuvant treatment for shoulder pain.

    Abstract
  • Review Article2020-09-30
    JoP

    Ethnomedicinal Uses, Phytochemistry and Pharmacology of Dorema Species (Apiaceae): A Review

    Elaheh Zibaee1, Mohammad Sadegh Amiri2, Zahra Boghrati1, Faeghe Farhadi3, Mahin Ramezani4,5, Seyed Ahmad Emami1*, Amirhossein Sahebkar6,7,8,9
    J Pharmacopuncture 2020; 23(3): 91-123 https://doi.org/10.3831/KPI.2020.23.3.91

    Abstract : The application of antique medical instructions, practices, skills and knowledge has been considered as the most affordable treatment in many developing countries. The use of these preparations and prescriptions over generations has made a useful and valuable guide for drug discovery in modern medicine. Medical herbs have been of a high importance for this purpose. The genus Dorema, of Apiaceae family (Umbelliferae) has a wide use in ethnobotany and traditional medicine around the world. It has been used as a treatment for CNS disease, convulsion, upper respiratory tract problems, gastrointestinal disorder and high blood sugar. Furthermore, phytochemical investigations have reported Dorema species to contain a wide range of constituents including terpenes, coumarins and phenolic compounds. The current review summarizes comprehensive information regarding botany, phytochemistry andpharmacological aspects of Dorema spp.

    Abstract
All Newest Articles
  • Review Article2020-06-30

    Abstract : Coronavirus disease-19 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). Currently, the management of patients with COVID-19 depends mainly on repurposed drugs which include chloroquine, hydroxychloroquine, lopinavir/ritonavir, ribavirin, remdesivir, favipiravir, umifenovir, interferon-α, interferon-β and others. In this review, the potential of Nigella sativa (black cumin seeds) to treat the patients with COVID-19 analyzed, as it has shown to possess antiviral, antioxidant, anti-inflammatory, anticoagulant, immunomodulatory, bronchodilatory, antihistaminic, antitussive, antipyretic and analgesic activities. PubMed, Google Scholar, Science Direct, Directory of open access journals (DOAJ) and reference lists were searched to identify articles associated with antiviral and other properties of N.sativa related to the signs and symptoms of COVID-19. Various randomized controlled trials, pilot studies, case reports and in vitro and in vivo studies confirmed that N.sativa has antiviral, antioxidant, anti-inflammatory, immunomodulatory, bronchodilatory, antihistaminic, antitussive activities related to causative oraganism and signs and symptoms of COVID-19. N. sativa could be used as an adjuvant therapy along with repurposed conventional drugs to manage the patients with COVID-19.

    Abstract
  • Review Article2020-09-30

    A Literature Analysis on Medicinal Use and Research of Cannabis in the Meiji Era of Japan

    Byung-Soo Ahn1,4, Seokhyun Kang2, Kyung Hoon Lee3, Seoyoon Kim1, Jin Sung Park1, Hyung-Sik Seo5*
    J Pharmacopuncture 2020; 23(3): 142-157 https://doi.org/10.3831/KPI.2020.23.3.142

    Abstract : Cannabis is a historical plant which has been used as a medicine in East Asia. These days, there are active debates about using cannabis in clinical field. Collecting and comparing cannabis research articles which had been published in the Opening of Japan to spot the interactions between the traditional medicine of Japan, Rangaku which was established in Edo Period and the European medicine which is transferred after Perry Expedition is academically meaningful. This study searched publications, which were listed on Open-Access databases by Dec. 11th, 2019. We collected research articles which had been published from January 3rd, 1867 to July 30th, 1912 also known as Meiji era and uploaded on Open-Access databases. Our searching databases were J-stage, CiNii (Scholarly and Academic Information Navigator), Tokyo Metropolitan Library, The National Diet Library, IRDB (Institutional Repositories DataBase) and KAKEN (Grant-in-Aid for Scientific Research Database). Searching keywords were cannabis, hemp and all their Japanese synonyms and available combinations. We selected final 15 studies which met every selection criteria in the 346,393 collected studies. Cannabis was prescribed in Meiji era of Japan to alleviate pain and cure the digestive, respiratory, urinary, and nervous system diseases such as indigestion, asthma, tuberculosis, gonorrhea and its complications, insomnia, and nervous prostration. Cannabis was medically used in Meiji era of Japan and the reporting and sharing of its clinical effect was published on the medical journals like present days. There were already Cannabis regulations in that era, but its medicinal use was more liberated than nowadays. It may be a chance to reconsider the current legal system, which strictly controls the use of Cannabis.

    Abstract
  • Original Article2020-09-30

    Abstract : Objectives: Atopic dermatitis (AD) is a prevalent and chronic, pruritic inflammatory skin condition that can influence all age groups. AD is associated with a poor health-related quality of life. This randomized clinical trial was performed to compare the effectiveness of Olivederma (combination of aloe vera and virgin olive oil) or betamethasone regarding disease severity, quality of life, serum IgE and eosinophil count. Methods: Thirty-six AD patients were randomly allocated to topical Olivederma or betamethasone, and were followed for 6 weeks. Results: Total SCORAD severity scores showed significant decrease in both groups, while it was more prominent in Olivederma group (64.5% improvement in Olivederma vs. 13.5% improvement in Betamethasone, p-value < 0.001). Quality of life (DLQI questionnaire) of AD patients was significantly improved after 6 weeks treatment with Betamethasone (22.3%, p < 0.001) and Olivederma (60.7%, p-value < 0.001). Olivederma group showed a significantly lower DLQI score in comparison with Betamethasone treated patients after 6 weeks of therapy (p < 0.001). Improvements in eosinophil count and serum IgE was observed. Conclusion: In summary, this study shows that Olivederma is superior to topical Betamethasone after 6 weeks of therapy with regard to disease severity, quality of life and eosinophil count.

    Abstract
All Newest Articles

Scimago Journal & Country Rank

SCImago Journal & Country Rank